Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists
申请人:ADAMED PHARMA, S.A.
公开号:US11034688B2
公开(公告)日:2021-06-15
The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
本发明涉及新的4-(哌嗪-1-基)-2-(三氟甲基)-1H-吲哚和4-(哌嗪-1-基)-2-(三氟甲基)-1H-苯并咪唑,由式(I)表示,其中所有符号和变量如描述中所定义。这些化合物可用于预防和/或治疗选自以下组别的疾病:阿尔茨海默病、帕金森病、利维体痴呆症、痴呆症相关精神病、精神分裂症、妄想综合征和其他与服用精神活性物质有关或无关的精神病、抑郁症、各种病因的焦虑症、各种病因的睡眠障碍。